Ciribè Massimiliano, Cirillo Erika, Mammone Martina, Vallogini Giulia, Festa Paola, Piga Simone, Ferrazzano Gianmaria Fabrizio, Galeotti Angela
Dentistry Unit, Management Innovations, Diagnostics and Clinical Pathways, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Clinical Pathways and Epidemiology Unit, Medical Direction, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Biomedicines. 2024 May 29;12(6):1202. doi: 10.3390/biomedicines12061202.
Fixed appliance (FA) therapy predisposes patients to white spot lesions (WSLs). The F-ACP complex (amorphous calcium phosphate nanoparticles enriched with carbonate and fluorine and coated with citrate) has been effective for in vitro enamel remineralization. The aim of this study was to evaluate the efficacy of the F-ACP complex in remineralizing WSLs after FA therapy. One hundred and six adolescents (aged 12-20 years) were randomized into study and control groups after FA therapy. Patients in the study group were advised to use dental mousse containing F-ACP applied within Essix retainers for six months. The presence of WSLs was recorded at baseline (T0), 3 months (T1), and 6 months (T2) according to the International Caries Detection and Assessment System (ICDAS). Visual Plaque Index (VPI) and Gingival Bleeding Index (GBI) were recorded. Among 106 study participants, 91 (52 and 39 in study and control groups, respectively) completed the study. The results showed that the ICDAS score was significantly lower ( < 0.001) in the study group than in the control group between T0 and T2. The application of mousse containing the F-ACP complex inside Essix retainers for six months is effective in remineralizing white spot lesions in patients after FA therapy without side effects.
固定矫治器（FA）治疗易使患者出现白斑病变（WSLs）。F-ACP复合物（富含碳酸盐和氟并包裹有柠檬酸盐的无定形磷酸钙纳米颗粒）已被证明对体外牙釉质再矿化有效。本研究的目的是评估F-ACP复合物对FA治疗后WSLs再矿化的疗效。106名青少年（年龄在12至20岁之间）在FA治疗后被随机分为研究组和对照组。研究组患者被建议使用含F-ACP的牙用泡沫，将其置于Essix保持器内使用6个月。根据国际龋病检测与评估系统（ICDAS）在基线（T0）、3个月（T1）和6个月（T2）记录WSLs的存在情况。记录视觉菌斑指数（VPI）和牙龈出血指数（GBI）。在106名研究参与者中，91人（研究组52人，对照组39人）完成了研究。结果显示，在T0至T2期间，研究组的ICDAS评分显著低于对照组（<0.001）。在Essix保持器内使用含F-ACP复合物的泡沫6个月，对FA治疗后的患者白斑病变再矿化有效且无副作用。
